US equities
|
NVDA
$178.67
▼-4.27%
AMD
$508.58
▲+13.26%
MU
$733.15
▲+6.25%
AAPL
$350.69
▲+2.43%
SPCX
$142.07
▲+5.81%
MSFT
$545.18
▲+2.75%
AMZN
$266.93
▲+2.94%
TSLA
$378.05
▲+5.54%
NVDA
$178.67
▼-4.27%
AMD
$508.58
▲+13.26%
MU
$733.15
▲+6.25%
AAPL
$350.69
▲+2.43%
SPCX
$142.07
▲+5.81%
MSFT
$545.18
▲+2.75%
AMZN
$266.93
▲+2.94%
TSLA
$378.05
▲+5.54%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Atea Pharmaceuticals, Inc. - common stock
(NQ:
AVIR
)
4.410
+0.100 (+2.32%)
Delayed Quote
Updated: 4:00 PM EST, Nov 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atea Pharmaceuticals, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Atea Pharma (AVIR) Q3 2026 Earnings Call Transcript
↗
Today 20:00 EST
Phase 3 hepatitis C data met its endpoints and funding now extends into mid-2028.
Via
The Motley Fool
Topics
Earnings
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Narrower Q3 Loss as C-FORWARD Readout Looms
↗
Today 19:28 EST
Via
Chartmill
What Atea Pharmaceuticals (AVIR) Said on Its Q3 Earnings Call
↗
Today 19:14 EST
Atea Pharmaceuticals (NASDAQ:AVIR) is targeting a mid-2027 U.S. application for its hepatitis C treatment, pending results from a second late-stage trial, and has secured a credit facility of up to...
Via
MarketBeat
Topics
Earnings
Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Today 16:05 EST
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom
↗
May 12, 2026
Via
Chartmill
Atea Pharmaceuticals (NASDAQ:AVIR) Reports Q4 2025 Results as HCV and HEV Pipeline Advance
↗
March 05, 2026
Via
Chartmill
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
Today 7:00 EST
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
November 02, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
September 08, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea (AVIR) Q2 2026 Earnings Call Transcript
↗
August 19, 2026
HCV regimen met non-inferiority with 8-week dosing for non-cirrhotic patients.
Via
The Motley Fool
Topics
Earnings
Atea Pharmaceuticals Q2 Earnings Call Highlights
↗
August 12, 2026
Atea Pharmaceuticals (NASDAQ:AVIR) reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and...
Via
MarketBeat
Topics
Earnings
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
August 05, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
July 28, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
July 14, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
June 25, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
May 27, 2026
Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E Virus
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
May 13, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Q1 Earnings Call Highlights
↗
May 12, 2026
Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no...
Via
MarketBeat
Topics
Earnings
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
May 05, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharma (AVIR) Earnings Call Transcript
↗
March 05, 2026
Atea Pharma (AVIR) Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 05, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
February 26, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
February 24, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
↗
February 03, 2026
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Via
The Motley Fool
Topics
Regulatory Compliance
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
↗
February 03, 2026
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Via
The Motley Fool
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
January 08, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Get insights into the top gainers and losers of Thursday's after-hours session.
↗
January 01, 2026
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
